

ID	Project Title	Collaboration Partners (Designated Development Partner is #1)	Disease	Intervention	Stage	Awarded Amount (¥)	Awarded Amount (S)	Continuing
G2017-203	Preclinical development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis	1. DNDi 2. Takeda Pharmaceutical Company Limited	Leishmaniasis	Drug	Preclinical Development, Clinical PhI	¥604,775,700	\$5,636,307	G2014-208
G2017-211	Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission-blocking vaccine: AnAPN1 v. 2.0.	1. University of Florida 2. CellFree Sciences Co. Ltd. 3. Ology Bioservices Inc. 4. Hamamatsu Pharma Research (HPR) 5. Infectious Disease Research Institute (IDRI) 6. Centre Pasteur du Cameroon (CPC)	Malaria	Vaccine	Preclinical Development	¥348,421,798	\$3,247,174	G2015-214
G2017-101	Lead optimization of novel azetidine-based tryptophan synthase inhibitors as new mechanism of action treatment of tuberculosis	1. Broad Institute 2. Eisai Co. Ltd. 3. Colorado State University 4. The University of Chicago 5. TB Alliance	Tuberculosis	Drug	Lead Optimization	¥200,332,434	\$1,867,031	New
H2017-101	HTL for selective Plasmodium proteasome inhibitors as new potent resistance-reversing antimalarials	1. Medicines for Malaria Venture (MMV) 2. The University of Melbourne's Bio21 Molecular Science and Biotechnology Institute 3. Takeda Pharmaceutical Company Limited	Malaria	Drug	Hit-to-Lead	¥46,124,588	\$429,866	T2015-134
H2017-102	New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo	1. Medicines for Malaria Venture (MMV) 2. Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo)	Malaria	Drug	Hit-to-Lead	¥44,550,000	\$415,191	S2014-211
H2017-103	Neglected Tropical Diseases Drug Discovery Booster III	1. DNDi – Drugs for Neglected Diseases initiative 2. Eisai Co. Ltd. 3. Shionogi & Co., Ltd. 4. Takeda Pharmaceutical Company Ltd 5. Astellas Pharma Inc.	Chagas disease, VL	Drug	Hit-to-Lead	¥149,832,868	\$1,396,392	H2016-203
S2017-221	Chagas disease and Leishmaniasis Screening between DNDi and Daiichi Sankyo Novare	1. DNDi 2. Daiichi Sankyo RD Novare Co., Ltd.	Chagas disease, VL	Drug	Hit Identification	¥11,900,000	\$110,904	New
T2017-272	Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine	1. Lygature 2. Institute of Tropical Medicine, Nagasaki University (NUTM) 3. Department of Parasitology, Leiden University Medical Center (LUMC)	Schistosomiasis	Diagnostics	Concept Development	¥76,389,000	\$711,920	New
T2017-274	Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator	1. The Pennsylvania State University 2. Institute of Tropical Medicine, Nagasaki University 3. Antigen Discovery, Inc.	Malaria	Vaccine	Antigen Identification	¥88,190,035	\$821,902	New
T2017-278	Target determination and exploratory research for discovery of new drugs against Chagas disease	1. Nagasaki University (NEKKEN) 2. National Institute of Advanced Industrial Science and Technology (AIST) 3. High Energy Accelerator Research Organization (KEK) 4. London School of Hygiene and Tropical Medicine (LSHTM)	Chagas Disease	Drug	Target Identification	¥88,235,010	\$822,321	New

\*All amounts are listed at the exchange rate of USD1 = JPY107.3, the approximate exchange rate on February 28, 2018.